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Clinical application of mesenchymal stromal cells (MSCs) usually requires an in vitro expan-
sion step to reach clinically relevant numbers. In vitro cell expansion necessitates supple-
mentation of basal mammalian cell culture medium with growth factors. To avoid using
supplements containing animal substances, human platelet lysates (hPL) produced from
expired and pathogen inactivated platelet concentrates can be used in place of fetal bovine
serum. However, globally, most transfusion units are currently not pathogen inactivated. As
blood banks are the sole source of platelet concentrates for hPL production, it is important to
ensure product safety and standardized production methods. In this proof-of-concept study
we assessed the feasibility of producing hPL from expired platelet concentrates with patho-
gen inactivation applied after platelet lysis by evaluating the retention of growth factors, cyto-
kines, and the ability to support MSC proliferation and tri-lineage differentiation.
Methodology/Principal findings
Bone marrow-derived MSCs (BM-MSCs) were expanded and differentiated using hPL
derived from pathogen inactivated platelet lysates (hPL-PIPL), with pathogen inactivation
by amotosalen/ultraviolet A treatment applied after lysis of expired platelets. Results were
compared to those using hPL produced from conventional expired pathogen inactivated
platelet concentrates (hPL-PIPC), with pathogen inactivation applied after blood donation.
hPL-PIPL treatment had lower concentrations of soluble growth factors and cytokines than
hPL-PIPC treatment. When used as supplementation in cell culture, BM-MSCs proliferated
at a reduced rate, but more consistently, in hPL-PIPL than in hPL-PIPC. The ability to sup-
port tri-lineage differentiation was comparable between lysates.
Conclusion/Significance
These results suggest that functional hPL can be produced from expired and untreated
platelet lysates by applying pathogen inactivation after platelet lysis. When carried out post-
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expiration, pathogen inactivation may provide a valuable solution for further standardizing
global hPL production methods, increasing the pool of starting material, and meeting future
demand for animal-free supplements in human cell culturing.
Introduction
Pathogen inactivation systems are proactive alternatives to conventional bacterial screening
and prevention methods for blood transfusion products [1]. Several systems are currently avail-
able on the market such as the INTERCEPT™ Blood System, Mirasol™ and THERAFLEX™ [2].
The INTERCEPT™ Blood System for pathogen inactivation of platelets gained the CE mark in
2002 [3] and is routinely used in several European countries [4]. The system effectively reduces
the accumulation of pathogens by blocking their ability to replicate [3]. The active compound
used in the INTERCEPT System, amotosalen S-59, passes through cell membranes, bacterial
walls, and viral envelopes and intercalates between helical regions of DNA and RNA [5]. Cova-
lent crosslinks are formed between amotosalen S-59 and pyrimidine bases upon exposure to
ultraviolet A (UVA) illumination, leaving most pathogenic organisms unable to replicate [3].
While successful inactivation is observed in general, non-enveloped viruses such as hepatitis A
and hepatitis E show resistance to the treatment [3].
Implementing a pathogen inactivation system improves the safety of transfusion units and
allows platelets to be stored for an extended period of up to seven days [3]. Blood banks must
stock surplus transfusion units; with approximately 2 million reported annual platelet transfu-
sions in the United States alone [6], this inevitably results in large quantities of expired platelets
[7]. Although expired platelet concentrates are unfit for transfusion medicine due to safety
concerns, their abundance of growth factors makes them suitable for use in cell cultures [8].
Human mesenchymal stromal cells (MSCs) are multipotent cells capable of undergoing in
vivo differentiation into end-stage cell types of connective tissues [9]. They were initially
described, in the 1960s, as plastic-adherent and fibroblast-like cells with clonogenic potential
in vitro [10]. Today, they are recognized as a part of stem cell niches in the bone marrow [11]
and are known to play a role in immunomodulation [12], as demonstrated by the prominent
contribution of the cells in reversing graft-versus-host-disease [13]. Scientific interest in MSCs
has developed in recent years, making them one of the most-studied human cell types related
to cell-based therapy [14].
An in vitro expansion step is usually necessary to attain clinically relevant numbers of
MSCs [15]. Successful expansion of MSCs requires that basal cell culture medium be supple-
mented with a source of mitogens, such as growth factors. To date, this has mostly been per-
formed using fetal bovine serum (FBS), which contains low amounts of immunoglobins and
complement factors [16]. However, concerns regarding the content of animal components
and large lot-to-lot variability has initiated a quest for replacements [16–18]. Platelet deriva-
tives such as human platelet lysates (hPL) are currently considered promising replacements
for FBS [8,19–22] due to their non-xenogeneic nature and abundance of growth factors [23].
hPL has successfully been produced from fresh platelets [24], expired platelets [8], and, most
recently, from expired and pathogen inactivated platelets [22]; all have been found to either be
comparable to or to outperform FBS.
hPL is commonly manufactured by exposing platelet concentrates to repetitive cycles of
freezing and thawing, resulting in degranulation [21], but it can also be produced by CaCl2
activation [25], sonication [26], or by using a solvent/detergent strategy [27]. Degranulation
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causes the α-granules to release growth factors and cytokines into solution [28]. To obtain a
sufficient volume of hPL, allogeneic hPL are typically pooled using up to 120 donors [29]; how-
ever, recent research has demonstrated that pooling can be done effectively using up to 250
donors [30]. The end product is refined by centrifugation and sterile filtration to remove plate-
let fragments [29].
Recently, emphasis has been placed on improving standardization in global good
manufacturing practice (GMP)-grade hPL production, as current production methods vary
between manufacturers [31]. Although pathogen inactivation techniques have recently been
introduced into the preparation of transfusion products, they are predominantly applied in
Europe, while blood banks in the United States and Asia primarily rely on bacterial screening
systems such as BacT/ALERT to ensure product safety [32]. As a result, most platelets used for
hPL production are currently not pathogen inactivated.
In this proof-of-concept study, hPL from pathogen inactivated platelet lysates (hPL-PIPL),
where pathogen inactivation was applied after lysis of expired platelets, was compared to hPL
produced from expired conventionally pathogen inactivated platelet concentrates (hPL-PIPC),
where pathogen inactivation was applied after production of platelet concentrates. We evalu-
ated and compared the total protein content and concentrations of selected soluble growth fac-
tors and cytokines between hPL-PIPL and hPL-PIPC. Furthermore, we compared long-term
proliferation and tri-lineage differentiation of bone marrow-derived MSCs using hPL-PIPL
and hPL-PIPC as cell culture media supplements in order to determine the feasibility of pro-
ducing an effective cell culture supplement from hPL when pathogen inactivation is applied
after platelet lysis.
Results
Growth factor and cytokine concentrations are lower in hPL-PIPL than in
hPL-PIPC
Quantification of 37 soluble growth factors and cytokines was performed using Luminex
xMAP technology following platelet lysate production. Each of the measured growth factors
and cytokines was present at lower concentrations in hPL-PIPL than in hPL-PIPC (Table 1).
The mean decreases for all evaluated growth factors and cytokines in hPL-PIPL (as compared
to hPL-PIPC) for two produced batches were 29 ± 15% (p< 0.001) and 36 ± 19% (p< 0.001).
The mean differences between hPL-PIPL and hPL-PIPC in key growth factors for the two
batches ranged from 4.2 to 36%: platelet-derived growth factor-AB/BB (PDGF-AB/BB)
(4.2 ± 1.8%); platelet-derived growth factor-AA (PDGF-AA) (12 ± 17%), epidermal growth
factor (EGF) (23.9 ± 7.8%); vascular endothelial growth factor (VEGF) (26.6 ± 0.62%); and
basic fibroblast growth factor (FGF-2) (36.3 ± 1.8%).
Proliferation of MSCs in hPL-PIPL is comparable to, but slower than, that
in hPL-PIPC
Proliferation of MSCs originating from the bone marrow of two individual donors were
assessed during nine cell passages (Fig 1). Cumulative population doublings (CPDs) were
assessed from passage 4 through passage 9. MSCs grown in cell culture media supplemented
with hPL-PIPL (hPL-PIPL-MSCs) proliferated significantly slower than hPL-PIPC-MSCs
(p< 0.001) from passage 5 through passage 9. At the end of passage 9, MSCs from Donor 6
had reached 19.42 ± 0.10 CPDs and 21.25 ± 0.03 CPDs with hPL-PIPL and hPL-PIPC supple-
mentation, respectively, and MSCs from Donor 13 had reached 10.50 ± 0.40 CPDs and
12.80 ± 0.20 CPDs.
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Table 1. Growth factor and cytokine concentrations in two batches of undiluted hPL.
Growth Factor / Cytokine Batch 23 Batch 24 Batch 23 vs. Batch 24
hPL-PIPC hPL-PIPL Differencea hPL-PIPC hPL-PIPL Difference Mean ± SDb
pg/mL pg/mL % pg/mL pg/mL % %
EGF 1992 1361 32 346 291 16 22.9 ± 7.8
Eotaxin 96 53 45 129 88 32 38.2 ± 6.7
FGF-2 517 320 38 478 313 34 36.3 ± 1.8
Fractalkine 234 196 16 164 105 36 26 ± 10
G-CSF 49 27 44 57 27 53 48.5 ± 4.1
GM-CSF 27 20 26 27 14 48 37 ± 11
IFNα2 76 49 35 84 44 47 41.2 ± 6.2
IFNγ 14 12 19 14 8.5 40 29 ± 11
IL-1α 59 50 16 29 19 35 25.4 ± 9.6
IL-1β 5.5 3.4 38 6.4 2.6 59 48 ± 11
IL-1RA 503 452 10 1030 884 14 12.2 ± 2.0
IL-2 7.8 6.1 23 4.0 1.8 55 39 ± 16
IL-3 6.3 4.3 32 6.2 3.1 49 40.6 ± 8.4
IL-4 31 17 47 48 27 44 45.5 ± 1.1
IL-5 34 28 16 82 69 16 15.7 ± 0.0
IL-6 13 7.9 40 12 3.3 72 56 ± 16
IL-7 30 20 32 36 22 40 36.4 ± 3.9
IL-8 50 38 24 76 64 16 19.9 ± 3.8
IL-9 10 7.2 29 6.5 3.9 39 34.3 ± 5.0
IL-10 20 14 30 7 2.4 65 48 ± 18
IL-12p40 61 51 16 62 32 49 33 ± 16
IL-12p70 11 6.2 44 12 6.2 47 45.5 ± 1.5
IL-13 183 176 3.7 433 372 14 8.8 ± 5.2
IL-15 12 6.6 45 8.6 3.6 59 51.6 ± 7.1
IL-17A 14 14 4.1 10 5.5 43 23 ± 19
IP-10 120 58 52 101 51 49 50.7 ± 1.4
MCP-1 157 111 30 185 157 15 22.4 ± 7.4
MCP-3 301 276 8.3 520 491 5.7 7.0 ± 1.3
MDC 705 192 73 754 230 69 71.1 ± 1.7
MIP-1α 24 22 11 33 30 8.8 9.8 ± 1.0
MIP-1β 123 82 34 165 127 23 28.4 ± 5.4
PDGF-AA 15850 11232 29 9105 9548 -4.9 12 ± 17
PDGF-AB/BB 27802 27146 2.4 25157 23661 5.9 4.2 ± 1.8
TGF-α 3.0 1.8 40 4.1 1.9 53 46.5 ± 6.5
TNFα 24 16 35 26 15 42 38.5 ± 3.5
TNFβ 266 236 11 570 490 14 12.7 ± 1.4
VEGF 538 392 27 441 327 26 26.6 ± 0.6
Mean ± SD (%) 29 ± 15 36 ± 19 32 ± 16
p-valuec < 0.001 < 0.001 < 0.001
a Difference (%) between hPL-PIPC and hPL-PIPL within individual batches (Batch 23 and Batch 24). Note that the concentrations for all growth factors and cytokines
were lower in hPL-PIPL.
b Mean ± SD (%) represents the mean difference between hPL-PIPC and hPL-PIPL for both batches (n = 4).
c p-values are reported on the overall differences between treatments (hPL-PIPC and hPL-PIPL) in individual batches (23 and 24) and for both batches combined. p-
values were determined using a paired ratio t-test.
https://doi.org/10.1371/journal.pone.0220163.t001
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Tri-lineage differentiation is not affected by the timing of pathogen
inactivation
hPL-PIPL-MSCs were successfully differentiated into osteogenic, adipogenic and chondrogenic
lineages. Osteogenic differentiation was evaluated during 28 days of stimulation in osteogenic
media. Alkaline phosphatase (ALP) activities in both hPL-PIPL-MSCs and hPL-PIPC-MSCs
were significantly elevated after seven days as compared to unstimulated control cultures
(p< 0.05) (Fig 2). A peak in ALP activity was observed at day 14 for both hPL-PIPL-MSCs
(3.6 ± 0.1 nmol (p-nitrophenol)/min) and hPL-PIPC-MSCs (3.8 ± 0.1 nmol (p-nitrophenol)/
min), followed by fairly consistent ALP activity between days 14 and 28. Comparable minerali-
zation between hPL-PIPC and hPL-PIPL MSCs was demonstrated by Alizarin Red S staining
after 28 days of differentiation (Fig 3A and 3B).
Adipogenic differentiation was evaluated during 14 days of stimulation in adipogenic
media. Accumulation of lipid droplets in the cell periphery was confirmed by positive Oil Red
O staining after 7 days. After 14 days of differentiation, lipid droplets were distributed
throughout the cells (Fig 3C and 3D).
Chondrogenic differentiation was evaluated during 35 days of stimulation in chondrogenic
media. After 28 days of differentiation, the concentration of glycosaminoglycans (GAGs) was
significantly higher (p< 0.05) in cell pellets supplemented with both hPL-PIPC and hPL-PIPL
than in unstimulated control cell pellets (Fig 4). GAG concentration remained significantly
higher than the control during differentiation of hPL-PIPC-MSCs at day 35 (p< 0.05), while
GAG concentration decreased again in hPL-PIPL-MSCs by day 35 such that there was no
longer a significant difference from the control. No statistically significant differences were
observed between hPL-PIPC-MSCs and hPL-PIPL-MSCs. Lacunae formation and accumula-
tion of collagen fibers were demonstrated after 35 days of differentiation using Masson’s tri-
chrome staining (Fig 3E and 3F).
Fig 1. Long-term proliferation of MSCs, expressed as cumulative population doublings. Proliferation of MSCs from two donors (D6 and D13) was evaluated in
cell culture media supplemented with hPL-PIPC or hPL-PIPL after passage 3 (indicated by the vertical dotted line). Points represent mean ± SEM at the end of
each passage (n = 6 cell cultures per passage, assessed in two independent experiments). Asterisks (� p< 0.05) indicate statistical significance between hPL-PIPC
and hPL-PIPL for an individual donor, evaluated via a two-way ANOVA with Tukey’s post hoc test.
https://doi.org/10.1371/journal.pone.0220163.g001
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Discussion
In this proof-of-concept study, the feasibility of producing cell culture supplements from hPL
derived from pathogen inactivated platelet lysates (hPL-PIPL) was evaluated via a comparison
with a supplement created from conventional hPL derived from pathogen inactivated platelet
concentrates (hPL-PIPC). We evaluated the composition of the lysates as well as their applica-
bility for use as supplements to support BM-MSC proliferation and tri-lineage differentiation.
As it has previously been shown that hPL performance as a cell culture supplement is compa-
rable to or better than that of FBS [8. 22, 24], FBS was not included in this proof-of-concept
work.
Concentrations of all 37 selected soluble growth factors and cytokines were significantly
reduced in hPL-PIPL compared to hPL-PIPC, with an average difference of 32 ± 16%
(p< 0.001). Of the key growth factors, we found that the differences between hPL-PIPC and
hPL-PIPL in PDGF-AB/BB and PDGF-AA were relatively small, at 4.2 ± 1.8% and 12 ± 17%,
respectively. The effects on EGF, VEGF, and FGF-2 were slightly higher, with observed reduc-
tions in hPL-PIPL of 23.9 ± 7.8%, 26.57 ± 0.62, and 36.3 ± 1.8%, respectively. As several growth
factors within the α-granules of the platelets are important for MSC proliferation and differen-
tiation [33,34], the composition following production and storage is an important marker for
platelet lysate quality. The effects of pathogen inactivation on growth factor stability during
storage have previously been studied. It was demonstrated that UVC treatment of platelet con-
centrates had no effect on concentrations of EGF, FGF-2, PDGF-AB, VEGF, or insulin-like
growth factor (IGF) [35]. In a study specifically conducted on the INTERCEPT™ Blood System
Fig 2. Alkaline phosphatase activity during osteogenic differentiation. MSCs were differentiated in osteogenic media supplemented with hPL-PIPL or hPL-PIPC,
with MSCs grown in expansion media included as a control. Points represent means ± SEM (n = 6 cell cultures per timepoint, assessed in two independent
experiments). Asterisks (� p< 0.05) indicate statistical significance versus the control, evaluated via a two-way ANOVA with Tukey’s post hoc test.
https://doi.org/10.1371/journal.pone.0220163.g002
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for pathogen inactivation, it was found that amotosalen plus UVA treatment mainly targets
proteins of intracellular platelet activation pathways [36]. In addition, UV illumination of
platelets combined with riboflavin or amotosalen seems to trigger activation of p38 mitogen-
activated protein kinases (p38MAPK), leading to platelet degranulation [37]. However, to our
knowledge this is the first study evaluating the effect of pathogen inactivation on lysed platelets
compared to intact platelet concentrates. It can be speculated that, as a result of platelet cargo
being released into solution of hPL-PIPL at the time of pathogen inactivation, the difference in
composition between hPL-PIPC and hPL-PIPL is caused by UVA photodegradation, since
Fig 3. Tri-lineage differentiation of MSCs. MSCs differentiated using hPL-PIPC are shown in A, C, and E, while
MSCs differentiated using hPL-PIPL are shown in B, D, and F. A and B show Alizarin Red S staining, used to
demonstrate mineralization (black arrows) after 28 days of stimulation in osteogenic medium. C and D show Oil Red
O staining, used to demonstrate accumulation of lipid droplets (black arrows) after 14 days of stimulation in
adipogenic medium. E and F show Masson’s trichrome staining, used to demonstrate collagen fibers (black arrows)
and lacunae formation (yellow arrows) after 35 days of chondrogenic stimulation.
https://doi.org/10.1371/journal.pone.0220163.g003
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light exposure can lead to irreversible changes in the primary, secondary, and tertiary structure
of proteins [38]. It should be noted that the individual differences in soluble growth factors
and cytokines between the two batches produced in this study limits the ability to generalize
the results of changes to growth factors and cytokines beyond this proof-of-concept study.
As it has been suggested that hPL should contain high concentrations of PDGF-AB, VEGF,
EGF, FGF-2, and transforming growth factor beta 1 (TGF-β1), and low concentrations of IGF-
1, we examined the long-term proliferation of MSCs from two donors in terms of cumulative
population doublings (CPDs). Total CPDs were higher for both of the donor hPL-PIPC-MSCs
than for the hPL-PIPL-MSCs, indicating higher mitogenic effects in conventional hPL-PIPC.
It is evident that EGF and VEGF activate the Raf-MEK-ERK pathway by binding to transmem-
brane receptor proteins at the plasma membrane [39]. Less activation of the Raf-MEK-ERK
pathway may contribute to less cell proliferation and failure to prevent apoptosis. However, it
is important to mention that high CPDs should not be viewed as a success criterion in isola-
tion; successful expansion of MSCs must also include retention of genomic stability and avoid-
ance of tumorigenicity [40]. These parameters were not within the scope of this study, but to
fully elucidate the ability of hPL-PIPL to support long-term proliferation and clinical potential
of MSCs in vitro, genomic stability and tumorigenicity is important. Future work should con-
sider these factors.
Tri-lineage differentiation potential was examined in vitro by stimulating MSCs in osteogenic,
adipogenic, and chondrogenic media. After 14 days of differentiation, both hPL-PIPC-MSCs
and hPL-PIPL-MSCs differentiating into osteoblasts demonstrated significantly higher ALP
activity compared to unstimulated control cultures. The presence of peak ALP levels around day
Fig 4. Concentration of glycosaminoglycans. GAG concentration was measured in MSC pellets stimulated with chondrogenic media supplemented with either
hPL-PIPC or hPL-PIPL. Pellets grown in expansion media were included as a control. Points represent mean ± SEM (n = 2 pellets per timepoint, assessed in two
individual experiments). Asterisks (� p< 0.05) indicate statistical significance versus the control, evaluated via a two-way ANOVA with Tukey’s post hoc test.
https://doi.org/10.1371/journal.pone.0220163.g004
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14 is a marker for osteogenic differentiation [41] and, in our study, indicated osteogenic differen-
tiation potential. This was supported by mineralization and bone-like nodule formation after 28
days of differentiation in both treatments.
Adipogenic differentiation potential was evaluated over the course of 14 days. As mature
adipocytes predominantly consist of lipid droplets [42], we used positive Oil Red O staining to
visualize the transition from MSCs into adipocytes. Morphological alterations from spindle-
shaped MSCs toward round adipocytes were observed after 7 days in both hPL types. Similarly,
lipid droplets had formed at the periphery of the cells by day 7, and after 14 days the lipid drop-
lets took up most of the intracellular space.
Finally, we evaluated chondrogenic differentiation potential over a period of 35 days. Cell pel-
lets from both hPL-PIPC-MSCs and hPL-PIPL-MSCs had accumulated significantly more glycos-
aminoglycans (GAGs) after 28 days of differentiation than unstimulated control cultures. This
was consistent at day 35 for hPL-PIPC-MSCs, whereas the GAG concentration decreased between
days 28 and 35 for hPL-PIPL-MSCs. To evaluate changes within pellet structures, the pellets were
sectioned and stained with Masson’s trichrome. During differentiation, we observed lacunae for-
mation and collagen fiber formation, which confirmed successful chondrogenic differentiation.
Based on the preliminary results obtained from this study, it appears that the application of
pathogen inactivation techniques after platelet expiry and lysate production is possible and
may prove to be a valuable tool in the pursuit of optimal safety and standardization in thera-
peutic-grade human platelet lysate production. Despite decreased growth factors and cytokines
in hPL-PIPL compared to hPL-PIPC, levels were shown to be sufficient in hPL-PIPL to sup-
port MSC proliferation and differentiation into osteoblasts, adipocytes, and chondrocytes.
The results of this work imply that further research into the suitability of applying pathogen
inactivation to lysates from expired platelets is warranted. Given that this was a proof-of-con-
cept study, several limitations should be addressed in further research. Firstly, a larger number
of hPL batches should be evaluated in order to better evaluate the changes in growth factors
and cytokines based on the hPL production method, as there were large differences between
the two batches used in this study. A comparison to an FBS control would also be warranted,
in order to compare the levels of growth factors and cytokines in hPL-PIPL supplements to
those found in FBS supplements. In addition, it would be valuable to examine the effect of hPL
production method on genomic stability and tumerogenicity.
Conclusion
In this proof-of-concept study, we demonstrated that functional hPL cell culture supplements
can be produced by performing pathogen inactivation after platelet lysis of expired and previ-
ously untreated platelet concentrates (hPL-PIPL). hPL-PIPL supported long-term cell prolifer-
ation and tri-lineage differentiation of BM-MSCs. While hPL-PIPL performed comparably
to hPL-PIPC in terms of tri-lineage differentiation, lower cumulative population doublings
(CPDs) were observed for hPL-PIPL. hPL-PIPL was also found to contain lower concentra-
tions of key growth factors, suggesting that the timing of pathogen inactivation may affect the
mitogenic potential of hPL rather than differentiation potential. Further work is necessary to
evaluate the practical implications of the differences between hPL-PIPL, hPL-PIPC, and FBS
on the effectiveness of hPL-PIPL as a cell culture supplement.
Materials and methods
Preparation of platelet lysates
Study was approved by National Bioethics committee number VSN19-189. Four platelet con-
centrates (PCs) were prepared from a total of 32 buffy coats according to standard procedure
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at the Blood Bank, Landspitali (The National University Hospital of Iceland), Reykjavı́k, Ice-
land, as specified in Table 2. Two separate batches of PCs (batch nos. 23 and 24) were each
prepared by pooling two buffy coat-derived PCs together. Each pooled batch represented 16
whole blood donations obtained from healthy donors of the Blood Bank. Each batch was fur-
ther split into two units and exposed to pathogen inactivation at different timepoints. The first
unit, hPL-PIPC, was exposed to pathogen inactivation less than 24 hours post donation using
the INTERCEPT™ Blood System (Cerus Corporation, Concord, CA, USA), which involves
exposure to amotosalen S-59 and UVA illumination, according to manufacturer’s protocol.
Following pathogen inactivation, the PCs were placed into a platelet agitator at 22 ± 2˚C for
seven days until expiration, and then stored at -80˚C for three weeks prior to platelet lysate
production. The second unit, hPL-PIPL, was placed directly into the platelet agitator at
22 ± 2˚C without being pathogen inactivated, stored for seven days until expiration, and then
transferred to -80˚C storage for three weeks. Pathogen inactivation for this second unit was
performed after platelet lysis.
The expired PCs were collected and subjected to platelet lysis by three cycles of thawing at
37˚C and freezing at -80˚C to initiate degranulation. After the third cycle, the platelet lysates
were aliquoted in 50-mL centrifugation tubes (Corning Science, Reynosa Tamaulipas, Mexico).
Platelet fragments were removed by centrifugation at 4975 × g for 20 minutes using a Heraeus
Multifuge X3 (Thermo Scientific, Waltham, Massachusetts, USA). This centrifugation step was
repeated after the supernatants (platelet lysates) from each tube were transferred to new 50-mL
centrifugation tubes. Prepared lysates from each unit were pooled. The hPL-PIPC units were
distributed into 45 mL aliquots and stored at -20˚C in a freezer (Gram BioLine, Vojens, Den-
mark). In addition, 1 mL and 5 mL aliquots were prepared for composition analysis and adipo-
genic differentiation, respectively, and stored at -20˚C prior to analysis. The hPL-PIPL units
were injected into sterile bags (Cerus Corporation, Concord, CA, USA) and exposed to patho-
gen inactivation with the INTERCEPT™ Blood System, according to the manufacturer’s proto-
col, before being aliquoted and stored at -20˚C as above.
These undiluted platelet lysates were used for experimentation within 18 months of storage.
Growth factor and cytokine quantification
The undiluted platelet lysates were analyzed using Luminex xMAP Technology (EMD Milli-
pore Corporation, Billerica, MA, USA) to quantify 37 soluble growth factors and cytokines.
The Human Cytokine/Chemokine Magnetic Bead Panel (HCYTOMAG-60K, Millipore) was
used; it applies microspheres and fluorescent signaling to quantify EGF, Eotaxin, FGF-2, Frac-
talkine, G-CSF, GM-CSF, IFNα2, IFNγ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-9, IL-10, IL-12P40, IL-12P70, IL-13, IL-15, IL-17A, IL-1RA, IP-10, MCP-1, MCP-3, MDC,
Table 2. Platelet concentrate characteristics.
PC No. Number of buffy coatsa Mean platelet count (× 109) Batch no.
Total O+ O-
1 8 7 1 278 ± 88.6 23
2 8 4 4 211 ± 50.5 23
3 8 8 0 197 ± 40.2 24
4 8 5 3 195 ± 25.4 24
Total 32 24 8 220 ± 34.1
a Four buffy coat-derived platelet concentrates (PC) from donors with either O RhD positive (O+) or O RhD
negative (O-) blood groups comprised the starting material.
https://doi.org/10.1371/journal.pone.0220163.t002
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MIP-1α, MIP-1β, PDGF-AA, PDGF-AB/BB, TGF-α, TNFα, TNFβ, and VEGF. The concen-
trations in hPL-PIPL were compared to those in hPL-PIPC and expressed as percentage differ-
ence in relation to hPL-PIPC (Eq 1, where [GF/C]hPL‑PIPx refers to the concentration of a
particular growth factor or cytokine in the hPL-PIPC or hPL-PIPL treatment).
% Difference ¼




Mesenchymal stromal cells originating from the bone marrow of two healthy human donors
were purchased from Lonza (Walkersville, MD, USA) and stored at -180˚C in liquid nitrogen
prior to experimentation. The cells tested negative for viral infections and mycoplasma. Prior
to experimentation, the MSCs were cultured in a cell culture medium supplemented with
hPL-PIPC through passage 3. Subsequently, the MSCs were distributed into two cell culture
flasks supplemented with either hPL-PIPC or hPL-PIPL at the time of cell split (between pas-
sage 3 and passage 4). MSCs in passage 5 were used for experimentation.
The culture medium used was a complete cell culture medium (referred to as “expansion
medium” in this study) consisting of Dulbecco’s Modified Eagle Medium (DMEM) / F12 + Glu-
tamax supplement (Gibco, Grand Island, NY, USA) with 1% penicillin/streptomycin (Gibco)
and 2 IU/mL heparin (Leo Pharma A/S, Ballerup, Denmark), supplemented with a sufficient
amount of either hPL-PIPC (to produce hPL-PIPC-MSCs) or hPL-PIPL (to produce
hPL-PIPL-MSCs) to achieve a final concentration of 9%. Specifically, after allowing solutions to
reach ambient temperature, 50 mL of platelet lysate was centrifuged at 4975 × g for 10 minutes
and added to 500 mL DMEM / F12 + Glutamax along with 5 mL of penicillin/streptomycin and
200 μL heparin. The medium was allowed to sit for 10 minutes prior to sterile filtration. Sterile
filtration was performed using a 0.45 μm low protein-binding funnel (Corning Incorporated,
NY, USA) in a closed system. Finally, the medium was aliquoted into 45-mL centrifugation
tubes (Corning Incorporated) and stored at -20˚C until use. Once thawed for use in cell cultures,
the medium was maintained at 4˚C in a laboratory refrigerator (Angelantoni Life Sciences,
Massa Martana, Italy) for a maximum of seven days.
Incubation was done in a Steri-Cult CO2 Incubator, HEPA Class 100 (Thermo Scientific)
under the following conditions: 37˚C; 5% CO2, and 95% humidity.
Cell expansion was performed in different vessels appropriately selected for each experi-
ment at a seeding density of 6000 cells/cm2. For the initial cell expansion prior to experimenta-
tion, MSCs were expanded in 20 mL of expansion medium in Nunc™ EasYFlask™ 75 cm2 (T75)
cell culture flasks (Thermo Fischer Scientific Nunc A/S, Roskilde, Denmark). For long-term
proliferation studies, MSCs were expanded in 5 mL of expansion medium in Nunc™ EasY-
Flask™ 25 cm2 (T25) cell culture flasks (Thermo Fischer Scientific Nunc A/S). In both cases,
the expansion medium was replaced every two to three days.
Cell passaging was performed upon reaching 80–90% confluency, as determined visually by
daily inspection using a Leica DM IRB inverted contrast microscope (Leica Microsystems,
Wetzlar, Germany). In brief, the MSCs were gently washed with 1X PBS (Gibco) and dissoci-
ated from the surface in 0.25% 1X Trypsin-EDTA (Gibco) for 5 minutes. Preheated expansion
medium was added to neutralize the trypsin-EDTA before the cells were centrifuged at 609 × g
for 5 minutes. After centrifugation, the supernatant was discarded and the pellet was carefully
resuspended in 1 mL preheated medium prior to cell counting. The cells were diluted 5X by
mixing 20 μL resuspended cells, 30 μL 1X PBS, and 50 μL 0.4% trypan blue stain (Gibco) in a
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1.5-mL micro tube (SARSTEDT AG & Co., Nümbrecht, Germany). The cell solution was
loaded onto a hemocytometer (BRAND GMBH + CO KG, Wertheim, Germany), covered by a
glass, and counted at 50X magnification. Viable MSCs were identified by the retention of their
round morphology and by their lack of trypan blue uptake. Viable MSCs located in the four
corner squares were counted twice using the upper and lower chambers and averaged to esti-
mate the number of cells. If the sum of the four corner squares in a single chamber exceeded
200 viable MSCs, the cell solution was diluted further and the cell count repeated. Cell passag-
ing was completed by seeding 6000 cells/cm2 into a new cell culture vessel.
Long-term proliferation was evaluated by expanding and passaging MSCs in T25 cell cul-
ture flasks. Initially, MSCs entering passage 5 were seeded into six T25 cell culture flasks and
expanded in cell culture media supplemented with either hPL-PIPC or hPL-PIPL. The expan-
sion medium was replaced every two to three days, and cell passaging was carried out upon
reaching 80–90% confluency. All cell culture flasks were passaged on the same day and the
number of population doublings (PDs) was determined using Eq 2, where N0 and N1 repre-











Cumulative population doublings (CPDs) were expressed as the sum of the PDs obtained
in each passage. Cell expansion was terminated upon achieving recovery rates of less than
100% of the seeded cell number after a maximum of 14 days in culture. Daily monitoring was
performed to assess morphological alterations.
Tri-lineage differentiation
MSCs in passage 5 were used to evaluate in vitro tri-lineage differentiation potential. Osteo-
genic and adipogenic differentiation were performed simultaneously using the same cell cul-
tures. Chondrogenic differentiation was performed separately due to the large number of
required cells.
Osteogenic differentiation
Osteogenic differentiation was evaluated at various timepoints during 28 days of stimulation
in osteogenic medium. The osteogenic medium consisted of 45 mL DMEM / F12 + Glutamax
(Gibco) supplemented with 5 mL platelet lysate, 50 μL dexamethasone (Sigma-Aldrich,
St. Louis, MO, USA), 50 μL human/murine/rat BMP-2 (Peprotech, Rocky Hill, NJ, USA),
50 μL L-ascorbic acid (Sigma-Aldrich), and 108 mg β-glycerophosphate disodium salt hydrate
(Sigma-Aldrich). An increase in alkaline phosphatase activity and positive staining for miner-
alization were used as markers. In brief, 3500 cells/cm2 were seeded in quadruplicate in 6-well
tissue culture plates (Corning Incorporated) and in triplicate in 12-well tissue culture plates
(Corning Incorporated) for each timepoint. Control plates were included by seeding 5500
cells/cm2 in expansion media in absence of osteogenic stimulation. Plates were incubated at
37˚C, 5% CO2, and 95% humidity for up to 28 days. The cell culture medium was replaced
every two to three days. The left half of the 12-well plates was used to quantify ALP activity,
while the right half was used to detect mineralization by staining with Alizarin Red S.
Enzymatic activity of ALP was evaluated after 7, 14, 21, and 28 days of osteogenic differenti-
ation. Briefly, 0.02% Triton-X (Sigma-Aldrich) diluted in 1X PBS was added to all samples,
and then the cells were scraped off the surface and transferred to a 1.5-mL micro tube. The
cells were vortexed and then centrifuged at 13,200 × g for 15 minutes at 4˚C. After centrifuga-
tion, the supernatant was transferred to a new micro tube and mixed with 500 μL of p-
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nitrophenyl phosphate (pNPP) solution, prepared using SIGMAFAST™ pNPP and SIGMA-
FAST™ Tris Buffer (Sigma-Aldrich). Next, the solution was incubated for 45 minutes at 37˚C
protected from light, and the absorbance was measured at 400 nm. Each sample reading was
corrected by the average absorbance of three blank replicates. ALP activity (nmol (p-nitrophe-




x 1000 ; ð3Þ
where OD refers to the optical density obtained at 400 nm (-), 18.8 is the extinction coefficient
of p-nitrophenol (μmol-1), t is time (min), and 1000 is used to convert μmol to nmol.
Alizarin Red S staining was performed to visualize mineralization during osteogenic differ-
entiation. Cell cultures were collected and fixed in 4% paraformaldehyde after 7, 14, 21, and 28
days of osteogenic differentiation and stored at 4˚C prior to staining. Cells were washed three
times with distilled water (dH2O) before adding a 2% Alizarin Red solution containing Aliza-
rin Red S dye (Sigma-Aldrich) diluted in dH2O. The cells were placed on a rotating shaker and
stained for 20 minutes at room temperature, followed by four washing steps using dH2O. The
dye was allowed to dry for 24 hours by inverting the plates on paper towels. The following day,
images were captured using inverted contrast microscope imaging, and alterations in mor-
phology and formation of bone-like nodules were evaluated.
Adipogenic differentiation
Adipogenic differentiation was evaluated after 7 and 14 days of stimulation in adipogenic
medium. Adipogenic medium consisted of 22.5 mL StemPro1 Adipocyte Differentiation
Basal Medium (Gibco), 2.5 mL StemPro1 Adipogenesis Supplement (Gibco), 0.25 mL penicil-
lin/streptomycin, 2.5 mL platelet lysate, and 20 μL heparin.
In brief, 10,000 cells/cm2 were seeded in triplicate Nunc™ 9 cm2 Slideflasks (Thermo Fischer
Scientific Nunc A/S). Control slideflasks were included by seeding 5500 cells/cm2 in expansion
media in absence of adipogenic stimulation. Sideflasks were incubated at 37˚C, 5% CO2, and
95% humidity for up to 14 days. The MSCs were allowed to reach a confluency of 50–70% in
expansion media prior to introduction of the adipogenic medium. The cell culture medium
was replaced every two to three days. Cultures in the 9 cm2 slideflasks were washed three times
in 1X PBS and fixed in 3 mL of 4% paraformaldehyde and stored at 4 ˚C after 7 or 14 days
prior to Oil Red O staining.
Upon termination of the experiment, the slideflasks were collected and sent to the Depart-
ment of Pathology (Landspitali, Háskólasjúkrahús, Reykjavı́k, Iceland) where Oil Red O stain-
ing was performed according to departmental protocols. Positive Oil Red O-stained lipid
droplets were used as markers of adipogenic differentiation.
Chondrogenic differentiation
Chondrogenic differentiation was evaluated after 14, 28, and 35 days of stimulation in chon-
drogenic medium. Chondrogenic medium consisted of 47.9 mL DMEM / F12 + Glutamax
supplemented with 9% hPL, 1% penicillin/streptomycin, 50 μL L-ascorbic acid, 50 μL dexa-
methasone, 500 μL sodium pyruvate (Sigma-Aldrich), 500 μL L-proline (Sigma-Aldrich),
500 μL ITS+ (Gibco) and 5 μL of 10 ng/μL TGF-β3. Production of glycosaminoglycans, as well
as positive collagen fibers and lacunae formation visualized by chondrocytic pellet staining
with Masson’s trichrome were used as markers of chondrogenic differentiation.
In brief, 250,000 cells were seeded in ten 1.5-mL micro tubes containing 0.5 mL chondro-
genic media for each timepoint. Control micro tubes were included by seeding 250,000 cells in
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expansion media in absence of chondrogenic stimulation. Pellets were formed by centrifuga-
tion at 152 × g using a Sorvall Instruments RC5C centrifuge (Thermo Fischer Scientific). The
caps were punctured with a sterile needle to allow air exchange, and the tubes were incubated
at 37˚C, 5% CO2, and 95% humidity for up to 35 days. After 18–24 hours, the tubes were gently
agitated to detach the pellets from the wall of the micro tubes. To minimize the stress on the
pellets, half of the cell culture medium was replaced every second day. At each sampling time-
point (14, 28, and 35 days), three pellets were analyzed for GAG content and two pellets were
prepared for histological staining.
To prepare pellets for the GAG assay, the three pellets were pooled into a micro tube con-
taining 500 μL papain extraction reagent (Sigma-Aldrich). The samples were then transferred
to a Grant-Bio PHMT heating block (Grant Instruments Ltd, Shepreth, Cambridgeshire, UK)
and fully digested at 65˚C for a maximum of seven hours. After digestion, the samples were
centrifuged at 9660 × g and the supernatants were transferred to new micro tubes and stored
at -80˚C.
To prepare pellets for histological staining, the pellets were collected and washed in 1X PBS
prior to fixation in 0.5 mL 4% paraformaldehyde in new micro tubes. The samples were stored
at 4˚C prior to histological staining.
The Biocolor Blyscan Sulfated Glycosaminoglycan Assay B1000 (Biocolor Ltd, County
Antrim, United Kingdom) was used to quantify the concentrations of GAGs. The assay was
performed according to the manufacturer’s protocol. In brief, standards diluted in papain
extraction reagent were prepared containing GAGs in the working range of 0–5 μg/mL. 1 mL
of Blyscan dye reagent was added to a new micro tube prepared for each standard and sample.
100 μL of each standard and sample was then added to the new micro tubes and mixed with
the Blyscan dye reagent for 30 minutes on a mechanical shaker (Heidolph, Schwabach, Ger-
many). After incubation, the micro tubes were centrifuged for 10 minutes at 9660 × g. The
supernatant was separated from the pellet by inverting the micro tubes carefully before adding
0.5 mL dissociation reagent. Prior to quantification, the micro tubes were vortexed to release
bound dye into the solution. 200 μL of each standard and sample was loaded into a 96-well tis-
sue culture plate in triplicate and measured at 656 nm using a Multiskan1 spectrum spectro-
photometer (Thermo Scientific, Vantaa, Finland). The average absorbance of the blank
replicates was subtracted from each standard and sample. The GAG concentration of each
sample was determined using the standard curve. To express GAG concentration per pellet,
the values were divided by three to account for the number of pooled pellets.
Upon experimental termination, the micro tubes were collected and sent to the Department
of Pathology (Landspitali, Háskólasjúkrahús, Reykjavı́k, Iceland). Masson’s trichrome and
hematoxylin and eosin staining were performed according to departmental protocols.
Statistical analysis
Statistical comparisons were performed using GraphPad Prism Version 7.04 software (Graph-
Pad Software, Inc., San Diego, CA, USA). Paired t-tests were performed to analyze differences
in total protein. Ratio paired t-tests were performed to analyze differences in the content of
growth factors and cytokines. Differences in proliferation and differentiation were analyzed
using a two-way ANOVA followed by multiple comparisons using Tukey’s post hoc test. Dif-
ferences were considered significant at p< 0.05.
The sample size (N) for each experiment refers to the number of experimental units derived
from biological units using separate cell culture vessels. Nomenclature and principle were
adapted from Lazic et al. [43].
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We would like to thank Ragna Landrö for processing the platelet concentrates and Sigrún Bær-
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